Indeed it is less potent against GT2/3 in replicon assays I've seen (don't recall clinical data), but data from phase II of sofosbuvir/daclatasvir regimen were quite good in GT2/3:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.